Stocks Retreating on New Evolution: U.S. Bancorp (NYSE:USB), Radian Group Inc. (NYSE:RDN)

U.S. Bancorp (NYSE:USB) runs in leading trade, it increasing 1.55% to traded at $50.39. USB attains analyst recommendation of 2.80 on scale of 1-5 with week’s performance of 2.11%.

To find out the technical position of USB, it holds price to book ratio of 2.04 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 14.78, and price to earnings ratio calculated as 15.61. The price to earnings growth ration calculated as 3.38.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 2.80%, and looking further price to next year’s EPS is 5.31%. While take a short look on price to sales ratio, that was 6.61 and price to earning ration of 15.61 attracting passive investors.

Radian Group Inc. (NYSE:RDN) kept active in under and overvalue discussion, RDN holds price to book ratio of 1.11 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation. In addition, the firm has price to earnings ratio of 10.77, which is authentic method to judge but not universal for all situation.

Fundament/ News Factor in Focus

Taking look on ratio analysis, RDN has forward price to earnings ratio of 8.37, compare to its price to earnings ratio of 10.77. Adding one more ration to find detail valuation of security, price to earnings growth ration that stands at 0.99. The co is presenting price to cash flow as 68.81 and while calculating price to free cash flow it concluded at 11.61, the low single digit may indicate stock is undervalued and vise versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.

The firm has price volatility of 1.97% for a week and 2.59% for a month. Its beta stands at 2.25 times. Narrow down four to firm performance, its weekly performance was 2.34% and monthly performance was 12.57%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *